We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Rapid Fluorescence Fingerprinting Assay for Identification of Synthetic Cannabinoid Receptor Agonists

By LabMedica International staff writers
Posted on 14 Nov 2019
A team of British researchers developed a rapid real-time, point-of-care test for the identification of synthetic cannabinoid receptor agonists (SCRAs), a class of illegal drugs known colloquilly as “Spice” or “K2”.

SCRAs are a family of compounds designed to mimic the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD), the psychoactive molecules in cannabis, by binding to CB1 and CB2 cannabinoid receptors and acting as agonists for receptor function. More...
CB1 receptors are most commonly found in the peripheral and central nervous system, while the structurally smaller CB2 receptors are mostly expressed within the immune system. Under normal endogenous conditions, these cannabinoid receptors have been found to modulate a variety of physiological and cognitive processes including fertility, pregnancy, pre- and postnatal development, appetite, pain sensation, inflammation, mood, and memory, causing a number of major side effects, both psychological and physiological. These include, but are not limited to, acute kidney injury, vomiting, cardiovascular complications, agitation, irritability, confusion, hallucinations, delusions, psychosis, and even death. The severity of these side effects are thought to be due to SCRAs having unusually high binding affinities at CB receptors, coupled with acting as full agonists of CB receptors.

SCRAs are highly potent and addictive drugs that are prevalent in the prison system and among homeless populations in the United Kingdom. SCRAs are chemically diverse, with over a hundred compounds used as recreational drugs. The chemical diversity of SCRA structures presents a challenge in developing techniques to detect them. Typically, GC-MS is used for chemical identification; however, this technology is not usually available in most settings where detection is critical, such as in hospital emergency rooms, in jails or prisons, or among homeless communities.

In this light, investigators at the University of Bath (United Kingdom) sought to develop a real time, point-of-care method for identification of SCRAs.

In a recent paper, they reported that fluorescence spectral fingerprinting, which required only about five minutes to perform, could be used to identify the likely presence of SCRAs, as well as provide more specific information on structural class and concentration. Furthermore, the investigators demonstrated that that fluorescence spectral fingerprints, combined with numerical modeling, could detect both parent and burnt material, and that such fingerprinting was also practical for detecting them in saliva.

Senior author Dr. Chris Pudney, senior lecturer in biology and biochemistry at the University of Bath, said, "My partner is a psychiatrist and she was telling me that currently they do not have a way to confirm when they suspect spice use, they just do not know for sure. You can test for it with a urine or blood sample that is sent off to a lab, but that takes a few days and so in most cases it's pointless. I started looking into the chemistry and it is actually similar to something we have developed for detection of biological molecules. We decided on saliva because it seemed tractable and less invasive than some other options. We have proved the concept with a test that is simple and very accurate. The hardware is compact and portable and the results are easy to understand. We are working on software now, so that the user has a simple “one click” way to use it."

The fluorescence fingerprinting method was described in the September 5, 2019, issue of the journal Analytical Chemistry.

Related Links:
University of Bath


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.